Neuro-Oncology Conferences | Brain Tumor Conferences | Asia pacific | USA | Europe | Middle East | 2018

Theme: New Challenges and Latest Developments in Neuro Oncology and Treating Brain Tumour

Neuro Oncology 2017

ConferenceProgram

Renowned Speakers

Giulio Anichini
Imperial College NHS Trust, Imperial College of London
UK

Iulia Karlsson
Double Bond Pharmaceutical AB
Sweden

Wai Kwong Tang
The Chinese University of Hong Kong Hong Kong
China

Mohamed Hamdy Ibrahim

UAE

Josh Underwood
Vermont Academy
USA

Rala Aatif Mahmood
slamania medicals
Bahrain

Sandro lannaccone
San Raffaele hospital, Milan Italy
Italy

Neuro Oncology 2017

Dear Colleagues

As a member of the Organizing Committee it is my pleasure to invite you to attend Neuro Oncology and Brain Tumor 2017 in Dubai,UAE. The field of Neuro Oncology is unlimited with the help of Associations of neurooncology and brain tumour Societies.since it also covers neurological complications of systemic cancers. Paraneoplastic Neurological Syndromes represent an intriguing model of interaction between the immune system and tumours and could make an interesting contribution to knowledge of the aetiopathogenesis of tumour development and neuroimmunological disorders.

The time is right to review the state of the art of PNS at both a clinical and immunopathological level.

We look forward to bringing new knowledge to the table in Brisbane.

Bruno Giometto

Vice President

Italian Society of Neurology

Dear Delegates,

As a member of the Organizing Committee of the International Conference on Neuro Oncology and Brain Tumor (April24-25,2017) at Dubai, UAE, I am honoured to welcome you to this important event.

Neuro Oncology is a very complex field, where multi-disciplinarily is the leading word and it represents the only way to effectively tackle important and still unmet medical needs, such as treatment of brain tumors and management of treatment-related side effects. Innovative treatments, advances in neuro-imaging, improvement in the knowledge of cancer biology, palliative care and preclinical models will be among the main topics of the congress.

My field of research is focused on the side effect of chemotherapy on the peripheral nervous system, a small aspect of neuro-oncology. However, as a neurologist I am well aware of the relevance of the problems more broadly related to the diagnosis and care of brain tumor patients, and of the need of an intensive collaboration with neurosurgeons, radiotherapist, oncologist as well as other healthcare providers in order to optimize our efforts and to maximize their results.

This meeting is intended to allow you, irrespective to your personal expertise, to share opinions and to contact expert in all the multiple aspects of modern neuro-oncology. To this aim several tracks have been identified and the meeting program will be designed in order to facilitate contacts with the several opinion leaders who will guarantee the highest possible scientific level to each session or workshop.

I do really hope you will join us in Dubai to bring us your knowledge and to learn more on the most up-to-date aspects of the different facets of Neuro Oncology.

With best regards

Guido Cavaletti

President, Italian Peripheral Nerve Society

We are happy to welcome you to the upcoming 2^nd International Conference on Neuro Oncology and Brain Tumor held during April 24-25, 2017 at Dubai, UAE

In Dubai Every year about 2000 people are affected with brain and spinal cord tumors including children. Every year about 1,400 malignant brain Tumors are diagnosed in Dubai out of which about 100 of these cases in Children and About 80 people are diagnosed with other Malignant Central nervous system tumors, including malignant and spinal tumors, about in five of these are children. Patients diagnosed with glioblastoma, the most aggressive form of glioma, their prognosis remains poor with the majority of patients dying from the disease within the two years of diagnosis.

Track 1: Neuro Oncology

The central nervous system is denounced to various malevolent disorders. Central Nervous System covers its mechanism, ramification, Metastatic pestilence, Cancers, Neurons and Sensory Receptors, Neurological Disorders, Neurodegenerative disease and Imaging agents to CNS neurofibroma.

Global Central Nervous System Drugs market to grow at a CAGR of -3.2% over the period 2011-2015. The global central nervous system (CNS) therapeutics peddle has been forecast to reach US$133 billion by the year 2018, which increases in disease ubiquity rates due to increase in population, introduction of new drugs, and increased outgo on healthcare

3^rd International Conference on Neurological Disorders and Stroke April 24-26, 2017 Dubai, UAE: 3^rd International Conference on Brain Disorders and Therapeutics November 06-08, 2017 Valencia, Spain: 2^nd International Conference on Neuro Oncology and Brain Tumor April 24-25, 2017 Dubai, UAE: 11^th World Congress on Neurology and Therapeutics March 27-29, 2017 Madrid, Spain: 7th World Congress for Neurorehabilitation 2017 Vienna, Austria: Neuroradiology-Brain and Spine 2017 Sydney, Australia: Finnish Neurological Association, Georgian Society of Neurologists, German Society of Neurology, Italian Society of Neurology, Slovak Neurological Society, Swedish Neurological Society, European Academy of Neurology, European Paediatric Neurology Society

Track 2: Brain Cancer

Brain Cancer agora is segregate on the basis of diagnosis and therapeutics. A brain cancer involves the growth of idiosyncratic cells in the tissues of the brain. Cardinal brain cancer involves malignant tumor, Brain stem tumors, germ cell fibro adenoma, pituitary adenomas, Tumor development, DIPG, Cellular biology of brain cancer, primary CNS lymphomas, Pathophysiology and peril aspect of brain cancer and prognosis of brain tumors.

In 2011, 1,724 brain cancers were diagnosed in Dubai. The risk of being pronounced with a brain cancer by age 85 is 1 in 96 for men and 1 in 149 for women. In 2012, there were 1241 deaths in Dubai effectuate by brain cancer. The brain prognosis and tumour diagnosis regulates the market analysis of brain cancer

Key market players which make a part in this bailiwick are Antisense Pharma, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Hoffmann-La Roche Ltd, Genentech and others.

3^rd International Conference on Neurological Disorders and Stroke April 24-26, 2017 Dubai, UAE: 3^rd International Conference on Brain Disorders and Therapeutics November 06-08, 2017 Valencia, Spain: 2^nd International Conference on Neuro Oncology and Brain Tumor April 24-25, 2017 Dubai, UAE: 11^th World Congress on Neurology and Therapeutics March 27-29, 2017 Madrid, Spain: 7th World Congress for Neurorehabilitation 2017 Vienna, Austria: Neuroradiology-Brain and Spine 2017 Sydney, Australia: Finnish Neurological Association, Georgian Society of Neurologists, German Society of Neurology, Italian Society of Neurology, Slovak Neurological Society, Swedish Neurological Society, European Academy of Neurology, European Paediatric Neurology Society

Track 3.Central Nervous System Tumors

A central nervous system (CNS) tumor begins when healthy cells in the brain or the spinal cord change and grow uncontrollably, forming a mass. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A CNS tumor is especially problematic because a person’s thought processes and movements can be affected. This type of tumor also may be challenging to treat because the tissues around the tumor may be vital to the body’s functioning.

The brain is the centre of thought, memory, and emotion. It controls the five senses, which include smell, touch, taste, hearing, and sight. It also controls movement and other basic functions of the body, including heartbeat, circulation, and breathing. The spinal cord consists of nerves that carry information back and forth between the body and the brain.

Track 4: Pituitary Tumours

Pituitary tumours start in the pituitary gland which produces and helps regulate hormones. Pituitary tumours, sometimes called adenomas, are usually always benign. Symptoms can be caused by a tumour producing extra hormones, or by not producing enough hormones. Other symptoms, such as headaches or vision problems can be caused by the tumours pressing on the optic (eye) nerve .You will need different tests, such as eye tests, blood tests, a CT scan or a MRI scan. Your specialist will talk to you about the best treatment for you and explain the benefits and disadvantages.

Surgery is the most common treatment. The operation is done through the nose without having to open the skull. Radiotherapy is often used after surgery. Some people with very small tumours may have a specialised type of targeted radiotherapy called stereotactic radiosurgery.

Doctors sometimes treat tumours that produce a hormone called prolactin with drugs that reduce prolactin levels. If the whole pituitary gland is removed, you need to take drugs to replace the hormones that are normally produced (hormone replacement).

Track 5: Brain and Spine

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The central nervous system is so named because it integrates information it receives from, and coordinates and influences the activity of, all parts of the bodies of bilaterally symmetric animals that is, all multicellular animals except sponges and radially symmetric animals such as jellyfish and it contains the majority of the nervous system. Many consider the retina and the optic nerve (2nd cranial nerve), as well as the olfactory nerves and olfactory epithelium as parts of the CNS, synapsing directly on brain tissue without intermediate ganglia. Following this classification the olfactory epithelium is the only central nervous tissue in direct contact with the environment, which opens up for therapeutic treatments. The CNS is contained within the dorsal body cavity, with the brain housed in the cranial cavity and the spinal cord in the spinal canal. In vertebrates, the brain is protected by the skull, while the spinal cord is protected by the vertebrae, both enclosed in the meninges.

The spinal cord functions primarily in the transmission of neural signals between the brain and the rest of the body but also contains neural circuits that can independently control numerous reflexes and central pattern generators. The spinal cord has three major functions: as a conduit for motor information, which travels down the spinal cord, as a conduit for sensory information in the reverse direction, and finally as a center for coordinating certain reflexes.

Track 6: Glioblastoma

Glioblastoma multiforme (GBM) (specified as glioblastoma) is a presumptuous glioma which is developed from star-shaped glial units (i.e. astrocytes and oligodendrocytes) that stiffener the health of the nerve cellules within the brain. Almost1 in 5sarcoma in the brain are glioblastoma.

Glioblastoma multiforme occur most often in adults between the ages of 45 and 70 years. This carcinoma represents about 15.4% of all primary brain tumors and about 60-75% of all astrocytomas. They increase in recurrence with age, and affect more men than women. Only three per cent of childhood brain tumors are glioblastoma

Track 7: Metastatic Cancer

When cancer develops everywhere in the body and escalation (metastasizes) to the brain, which is called as secondary brain tumefaction, or metastatic brain cancer. Brain metastases (secondary brain tumors) occur in approximately 15% of cancer patients as a result of haematogenous proclamation, of cancer, and the incidence may be rising because of better control of integral disease.

The overall annual incidence of principal brain tumors in the United States is 9.5 cases per 100,000 populations. Over 60% of primary brain carcinoma are gliomas, and at least two-thirds of these are clinically aggressive and high category. Brain tumors represent 20% of all childhood malignancies and are the number two cause of cancer death in children after leukaemia

Track 8: Angiogenesis in Neuro Oncology

Angiogenesis theatrically a critical role in the maturation and spread of cancer, it also plays a major role in the transition of tumor cells from a benign state to a malignant (cancerous), leading to the use of angiogenesis evasion in the treatment of cancer.

Angiogenesis is a vital series that facilitates tumor growth and survival. Angiogenesis is a well-controlled path that is systematize by angiogenic, growth, and survival factors that are secreted by the malignant units as well as other corpuscle within the tumour microenvironment

Track 9 :Spinal Cord Tumors

Meningioma’s and neurofibromas, which originate in cells next to the cord, are the most common primary spinal tumors. They are noncancerous. Secondary spinal cord tumors , which are more common, are metastases of cancer originating in another part of the body and thus are always cancerous.spinal cord tumors are much less common than brain tumors. Spinal cord tumors may be primary or secondary.Primary spinal cord tumors may be cancerous or noncancerous. They may originate in the cells within or next to the spinal cord. Only about one third of primary spinal cord tumors originate in the cells within the spinal cord. These tumors can extend within the cord and cause a fluid-filled cavity (syrinx) to form.

Most primary spinal cord tumors originate in cells next to the spinal cord, such as those of the meninges—the layers of tissue that cover the spinal cord (see Figure: How the Spine Is Organized). Meningioma’s and neurofibromas, which originate in cells next to the cord, are the most common primary spinal tumors. They are noncancerous.

Secondary spinal cord tumors , which are more common, are metastases of cancer originating in another part of the body and thus are always cancerous. Metastases most commonly spread to the vertebrae from cancers that originate in the lungs, breasts, prostate gland, kidneys, or thyroid gland. Metastases usually put pressure on (compress) the spinal cord or nerve roots from the outside. Lymphomas may also spread to the spine and compress the spinal cord.

Track 10 : Radiation Oncology

Radiation Oncology encompasses all facet, of research that whack, on the treatment of cancer using radiation. It discloses verdict in molecular and cellular radiation oncology, radiation technology, radiation physics, and clinical oncology.

Radiation Oncology is fabricated up of three unique medical specialties that focus on the treatment of cancer patients with radiotherapy treatment (also known as radiation therapy);videlicet Radiation Oncologists, Radiation Therapists and Radiation Physicists.

Track 11: Diagnosis of Brain Tumours

The primary method which is used in the initial diagnosis, monitoring of response, and process of progression in Neuro oncology is neuroimaging techniques. Neuro imaging has enabled great progress in the diagnosis of brain cancer, as well as finding useful application in medical research and practice.

There are a number of accepted, safe imaging techniques in use today in research facilities and hospitals throughout the world which includes FMRI, CT scan, PET, EEG, MEG, and NIRS. This session includes latest technologies and developments of Structural and functional imaging, Biomarker Discovery, Radioactive compounds in Neuroimaging, Computed tomography, Diffuse optical imaging, Magnetic resonance imaging, Positron emission tomography.

Track 12. Pediatric Neuro Oncology

Pediatric Neuro-oncology is a sparkly developing field. Brain tumors are the fountainhead of cancer-related deaths aimed children. Brain disorders are the most common solid malignancy in children. Their bodies and brains are still developing, their tumors are different. The communal, childhood brain cancers are not the same as the most common adult brain cancers. Though they are sparse, brain tumors are very common form of solid tumors among children under the age of 15 and illustrate, about 20% of all childhood cancers.

Childhood tumors frequently appear in different locations and behave contradictory than brain tumors appearing in adults. Treatment options are different and can be vigorous pressurize by the age of the child. Children suffering from brain cancer may also occupy a much better prognosis than adults with a similar zone. The regular types of brain tumors in infants and children are Neurofibromatosis, Primitive Neuroectodermal tumor, Blood Cancer, Neuroblastoma, Medulloblastoma, Ependymoma and Astrocytoma.

Survival range for brain tumors vary widely superlatively on the type of tumor and other factors, including age. Five-year survival rates range from 66% for toddler; ages 0 - 19 years to 5% for adults age 75 years and older. Advancements in treatment have dramatically

Multiply survival rates for children with brain tumors. About 75% of children survive at least 5 years after being pronounced with a brain tumor. Brain cancers account for about 15% of pediatric cancers and are the second most common vintage of cancer in children. The specific treatment and prognosis depends on the grade, type, and location of the tumor. Depending on the genre of tumor and the timeliness of pronouncement , the 5 year survival growth rate is 40-80%.

Track 13. Neuropathology in Cancer

Neuropathology is the dissertation of contagion of nervous system tissue, usually in the form of either small surgical biopsies or whole autopsies. Neuropathology is a sub long-suit of anatomic pathology, neurology, and neurosurgery.

Work of the neuropathologist consists predominantly, of largely of examining biopsy tissue from the brain andspinal cord to aid in interpretation of disease. The biopsy is usually requested after a mass is detected by radiologic imaging. As for autopsies, the principal drudgery, of the neuropathologist is to help in the post-mortem diagnosis of various forms of dementia and other affliction that affect the central affect the central nervous system.

Track 14. Neuropsychology in Cancer

Clinical neuropsychologist is an expert in identifying, diagnosing and treating changes in a person's cognitive function (ability to think), personality, behavior and mood.

While brain tumor identification and localization are done primarily with MRI, the picture of the brain that's generated does not tell us about the functional impact of the lesion (such as a brain tumor) on a person's cognition, behavior and mood.

In addition, many treatments used to combat cancer also place normal healthy brain tissue at risk, which may result in changes incognition, behavior and mood that adversely affects quality of life and patients' abilities to maintain their occupational, academic or family and social roles.

Clinical history and interview - The neuropsychologist obtains information from the patient (and sometimes family and friends) about their symptoms, medical history and other important factors.

Cognitive testing - During this portion of the evaluation, patients are administered paper-and-pencil or computerized tests. There are no needles or painful machines.Recommendations - After the evaluation, the neuropsychologist puts together a report in which the pattern of cognitive strengths and weaknesses are described, diagnoses are rendered, specific referral questions are addressed and treatment plans are issued. These results are provided to the patient, family and their health care providers.

Track 15. Neurosurgery and Cancer

Neurosurgery is a complex surgical method that presupposes treatment, diagnosis, and rehabilitation of disorders affecting any region of the nervous system.Some of the preponderance common Neuro surgeries are skull base surgery, Image Guided Surgery, Laser Surgery , spinal Neurosurgery and Neuro surgical treatment. The Global Neurosurgery market is expected to raise 11.71% over the session of 2014-2019.

Neurosurgery session includes Image Guided Surgery, Laser Surgery,Surgical operation for brain fibro adenoma, spinal neurosurgery, skull base surgery, Neuro surgical treatment, Geriatric Neurosurgery, latest innovations and techniques.

Track 16. Pain Management

About one-third of patients are being analysed for cancer pain, which leads to many different forms. It may be short-lived or long-lasting, lenient or severe, or concomitant on few organs, bones or organ system. Since each patient’s pain is solitary, it is persuade that cancer pain management treatment plans must be adapt to address individual needs.

A market discernment, company based in the U.S, states that the Global pain management devices market was estimated at US$2.0 billion in 2011 and, estimated to pullulate, at a CAGR of 13.1% from 2011 to 2018, is predicted to reach the value of US$5.0 billion by 2018.

Track 17. Living with Brain Tumours

A brain tumor diagnosis is a life-altering event for anyone. When a brain tumor is diagnosed, it can take away your sense of security and control. This can be both unsettling and frightening. Uncertainty is among the most challenging aspects of a brain tumor diagnosis that you will have to deal with on a day-to-day basis. The feeling that your body has taken an unexpected direction often leads to a rollercoaster of emotions.

There will be days when you feel upbeat and positive and other days when you will feel that your world has caved in. Even with the best possible prognosis, you may be left wondering whether the tumor will return. This may lead you to begin examining other aspects of your personal and professional life.

There is no “right” way to behave or feel when you have been diagnosed with a brain tumor diagnosis. Dealing with changes to your appearance – such as losing your hair or losing weight is difficult for most of us. Keep in mind that your life is not so much “getting back to normal” as determining what is “normal” for you now. Your new “normal” may include making changes in the way you eat, the things you do, even your sources of support. Living with a brain tumor may mean rethinking your work and professional goals, looking at your life differently, or even experiencing a sense of new meaning.

Track 18. Neuro Pharmacology of Cancer

The anatomy, physiology, and pharmacology of nociception and its modification by analgesic drugs have been studied extensively in the past decade. Although the neural mechanisms of nociceptors and the stimuli that activate them are much better understood, it must be emphasized that the perception of pain, as well as the meaning of pain to the individual, is a complex behavioral phenomenon and involves psychologic and emotional processes in addition to activation of nociceptive pathways. Pain related to malignant disease can be classified as somatic, visceral, and deafferentation in type. Somatic pain and visceral pain involve direct activation of nociceptors and are often a complication of tumor infiltration of tissues or injury of tissues as a consequence of cancer therapy. The management of this type of pain is typically accomplished by treating the tumor (with surgery, chemotherapy, and/or radiation therapy) and by using the appropriate non-narcotic, narcotic, and adjuvant analgesic agents. Neuroablative therapies may be helpful in specific circumstances.

Track 19. Therapeutic Approaches

Brain malignancy market is segmented on the essence of diagnosis and therapeutics. Major research is going on targeted Therapies for Brain malignancy. On the basis of treatment the market is segmented into surgeries, radiation therapy, immunotherapy, chemotherapy and targeted analysis. Therapeutic approaches include Chemical therapy Intensity modulated radiation therapy, palliative custody, vaccine therapy, surgical delivery, Molecular pathology for clinician and challenges in analysis.

Global cancer drugs and treatments agora will reach $143.7 billion by 2023. The Anti-cancer treatment market is already worth $77.4 billion (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development.

Track 20. Case reports in Oncology

Brain Cancer clinical trials are research studies that test new and better ways to prevent, diagnose and treat Brain cancer. A world-first human trial has been set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say. According to the Cure Brain Cancer Foundation worth of $500,000 provided to the study over the next three years.

The Centre for Neuro Oncology offers the latest advances in care for adult patients with brain tumors or spinal cord tumors, as well as for neurologic complications of brain cancer and its treatments. The Australian Government is supporting Australia’s capacity to develop industry-independent cancer clinical trials.

We are happy to welcome you for the official website of 2^nd International Conference on Neuro Oncology and Brain Tumor during April 24-25, 2017 Dubai, UAE with the theme of New Challenges and Latest Developments in Understanding Neuro-oncology and treating brain tumour

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and Conference Series llc LTD. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

Overview of Neuro Oncology :

Quality of life is an important area of clinical Neuro-oncology and Brain tumour that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiform, and high-grade (highly anaplastic) astrocytoma are among the worst.

Geographically market is segmented into Europe, North America, Latin America, Asia pacific, and Middle East and Africa. According to market study, Market Value for Neuro Oncology (i.e on Brain Cancer and CNS Tumors) will be more than double to $ 623 Million by 2020. A major part of research is going on the top Universities on across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.

Why to attend?

International Conference on Neuro Oncology and Brain Tumor to bring together worldwide distinguished academics in the field of Neuro-oncologist, Oncologist, Radiation Oncologist, Medical Oncologists, Neuropharmacology, Neurology, Neuropediatricians, Pediatric Oncologists, Neurosurgeons, Neurophysiologists, Neuroscience Brain researchers, Public Health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. Attending International conference is for the Professional Development and to understand the current state of research and the challenges to future discovery

The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.

Target Audience

Directors, Head of Department, Professors, Industrial Researchers, Neuro-oncologist, Radiation Oncologists, Oncologists, Neuropediatricians, Neurophysiologists, Neurosurgeons, Neurologist, Neuroradiologist, Neuro-Pathologists, Rehabilitation Specialists , Nurses, Neuroscience Researchers and Students from academia in the research of Neuro-oncology. Neurooncology Associations, Brain tumour societies

Target Audience:

Academia: 65%

Industry: 25%

Others: 10%

About the conference:

ConferenceSeries llc LTD is organising a 2^nd International Conference on “Neuro Oncology and Brain Tumor” during April 24-25, 2017 Dubai, UAE. The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology. The Conference will help the Scholars to produce publishable quality of research papers.

ConferenceSeries Ltd is one of the leading organisation in conducting worldwide conferences which organizes 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums on various topics of Science & Technology across the globe with support from 1000 more scientific societies and Publishes 500+ Open Access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Overview of Neuro Oncology and Brain Tumor :

Quality of life is an important area of clinical Neuro Oncology and Brain Tumor that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies.Neurooncology associations and brain cancer societies take part of it.Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiform, and high-grade (highly anaplastic) astrocytoma are among the worst.

Importance and Scope:

Neuro-oncology and 2017 aims to faster the advancement of scientific knowledge that may ultimately result in a better prognosis for patients. International conference which is the Best platform to develop new partnership & collaborations .It provides an important base for the exchange of knowledge and experience amongst the clinicians and researchers involved in brain tumour research and patient management. The internationally renowned speakers at this conference will explore the clinical aspects of current Neuro-oncology research, quality of life issues and comprehensive patient care that takes into account the patient’s needs.

Why to attend?

International Conference on Neuro Oncology and Brain Tumor is to bring together worldwide distinguished academics in the field of Neuro oncologist , Oncologist, Radiation Oncologist, Medical Oncologists Neuropediatricians, Neurophysiologists, Neuropsychiatrists , Neuroscience and Neurology, Brain researchers, Public Health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. Attending International conference is for the Professional Development and to understand the current state of research and the challenges to future discovery.

Market Analysis:

Geographically market is segmented into Asia pacific,North America, Europe, Latin America and Middle East and Africa. According to market study, Market Value for Neuro Oncology Will More than Double to $623 Million by 2020. A major part of research is going on the top Universities on Neuro Oncology across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.

Why Dubai?

Malignant brain tumors and other central nervous system cancers represent highly challenging and devastating group of cancers ,Dubai has emerged as a global city and business hub of the Middle East. .Dubai was ranked 44th among the world's best financial cities and the world's 27th richest city in 2012. It is also an international financial center and has been ranked 37th within the top 50 global financial cities and 1st within the Middle East .According to a research report on the future competitiveness of cities, in 2025, Dubai will have moved up to 23rd place overall in the Index. Cancer research is mainly going on in Asian countries near to Dubai, so it is a suitable destination for radiation oncology conference. While the incidence of brain cancer is relatively low, mortality is high with the most recently reported 5-year survival rates at ~19–35% in Australia, United Kingdom, and America. The population of 23.6 million is highly urbanised and heavily concentrated in the eastern states and on the coast

Effect of Neuro Oncology across the Globe:

The incidence rate of all primary malignant and non-malignant brain and CNS tumors is 21.42 cases per 100,000 for a total count of 343,175 incident tumors; (7.25 per 100,000 for malignant tumors for a total count of 115,799 incident tumors and 14.17 per 100,000 for non-malignant tumors for a total count of 227,376 incident tumors). The rate is higher in females (23.26 per 100,000 for a total count of 198,212 incident tumors) than in males (19.42 per 100,000 for a total count of 144,963 incident tumors).

Major Associations of Neuro Oncology Worldwide:

Asian Society for Neuro-Oncology
Australian Oncology Social Work Inc.
SNO Society for Neuro Oncology
American Society of Clinical Oncology
American Brain Tumor Association
American Cancer Society
European Scientific Society
Canadian Cancer Society
National Brain Tumor Society

The UAE Government is supporting Dubai’s capacity to develop industry-independent cancer clinical trials. The following National Cancer Cooperative Trials Groups are currently funded by Cancer in Dubai

Funds Providing Organisations:

American Brain Tumor Association (ABTA)
ACT Brain Tumor
Ben and Catherine Ivy Foundation
Brain Tumor Foundation of Canada (BTFC)
Brain Tumor Funder's Collaborative
Childhood Brain Tumor Foundation
Concern Foundation
Congressionally Directed Medical Research Programs
Gold Hirsh Foundation
Grey Ribbon Crusade
Matthew Larson Foundation
National Brain Tumor Society
NBTS & AANS/CNS Section on Tumors
Pediatric Brain Tumor Foundation
Pediatric Oncology Grants
Sontag Foundation

Key Market Players across the Globe:

AstraZeneca
Antisense Pharma
EMD Serono Inc.
GlaxoSmithKline
Bristol-Myers Squibb
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Novartis AG

Recent advances on drug Development in Dubai :

A world-first human trial set to begin in Dubai ,UAE has the potential to be one of the biggest breakthroughs in the treatment of brain cancer.
A new drug, Gliolan (aminolevulinic acid) is now being used in patients with glioblastoma multiforme (GBM) by some Australian neurosurgeons to improve intraoperative identification and visualisation of the margins between tumour and normal brain tissue. This in turn assists the surgeon to more completely remove the malignant tissue

Target Audience

Target Audience:

Academia: 65%

Industry: 25%

Others: 10%

A major part of research is going on the top Universities on Neuro Oncology across the globe like

Cern Medical Research
Stanford University in California
UC San Diego
University of Wolver Hampton
University of Chicago
University Hospital Heidelberg
University of Michigan Health System
Duke University in Durham, NC
Washington University in St. Louis, MO
University of California
Harvard Medical School
UCSF School of Medicine
Perelman School of Medicine
Yale School of Medicine
Maryland School of Medicine
Warren Alpert Medical School
University of Virginia.
University of Rochester Medical Centre

Hospitals in Dubai :

Aesthetics International
Al Baraha Hospital (Ministry of Health)
Al Amal Hospital (Ministry of Health)
Al Jalila Children's Specialty Hospital - opens 2013
Al Zahra Hospital Dubai, Al Barsha, Dubai
American Hospital Dubai
American British Surgical & Medical Centre
Armada Hospital, Jumeirah Lake Towers, Armada Towers, Dubai
Armada Medical Center JLT
Armada Medical Center, Jumeirah Lake Towers,Armada Towers, Dubai.
Aster Hospital
Awazen | Cosmetic, spa, skin care], hair care, weightloss surgeries, plastic surgeries; Abu Dhabi ( private )
Belhoul Speciality Hospital
Belhoul European Hospital
Canadian Specialist Hospital
City Hospital Dubai
Dental clinic Dubai
Dubai Hospital (Dubai Government DOHMS)
Dubai Herbal and Treatment Centre,
Dubai London Specialty Hospital
Emirates International Hospital
Exeter Medical Center, Jumeirah 1 Area, 4A Street, Villa 30, Dubai
Fillers clinic dubai.
International Modern Hospital.
Iranian Hospital.
Jahab Dubai Hospital
Latifa Hospital (known before as Al Wasl Hospital) (Dubai Government DOHMS)
Lifeline Hospital
Medcare Hospital
MyPedia Clinic [Pediatric Clinic in Dubai]
Neuro-Spinal Hospital (private neurosurgical referral hospital)
New Apollo Polyclinic, Karama, Dubai
NMC Specialty Hospital
Prime Hospital Dubai (private and luxurious)
Rashid Hospital (Dubai Government DOHMS)
Saudi German Hospital-Dubai
Silkor Laser Hair Removal
Welcare Hospital
Zulekha Hospital, AL Nahda, Dubai

Hospitals in Worldwide:

Leiden University Medical Centre
Royal Cancer Hospital
King’s College Hospital
Clatterbridge Centre for Oncology
Northampton General Hospital
Cambridge University Hospitals
University Hospital Southampton
Central Manchester University Hospitals
South end University Hospital
Kingston Hospitals
Bradford Hospital
Institute of Oncology, Ljubljana
Institute Gustave Roussy, Paris
Paterson Institute On Cancer Research,UK
Christie Hospitals
Wellington Hospital
Imperial College Hospital
Curie Institute
Cleveland clinic

List of cancer drugs approved by the FDA for use in brain tumors

Gliolan
TRXE-009
Temozolomide
Afinitor (Everolimus)
Afinitor Disperz (Everolimus)
Avastin (Bevacizumab)
Becenum (Carmustine)
Bevacizumab
BiCNU (Carmustine)
Carmubris (Carmustine)
Carmustine
Carmustine Implant
CeeNu (Lomustine)
Everolimus
Gliadel (Carmustine Implant)
Gliadel wafer (Carmustine Implant)
Lomustine
Methazolastone (Temozolomide)
Temodar (Temozolomide)

Organisation	Type	Amount
Accelerate Brain Cancer Cure	Grants	Upto $250K
American Brain Tumor Association (ABTA)	Grants	$75,000
Ben and Catherine Ivy Foundation	Grants	Upto $3 Million
Brain Tumor Funder's Collaborative	Grants	up to $100,000
Childhood Brain Tumor Foundation	Grants	Up to $30,000
Concern Foundation	Grants	$60,000
Goldhirsh	Grants	$600,000
Goldhirsh	Research Rewards	$100,000
Grey Ribbon Crusade	Grants	up to $70,000
Matthew Larson Foundation	Grants	up to $75,000
James S. McDonnell	Grants	$450,000
John McNicholas Glioma Scholar Award	Grants	$200,000
National Brain Tumor Society	Grants	$300,000
NBTS & AANS/CNS Section on Tumors	Grants	$75000
Pediatric Brain Tumor Foundation	Grants	$2.5 Million
Sontag Foundation	Grants	$600,000

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	April 24, 25 2017
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View

2^nd International Conference Neurooncology and Neurosurgery April 24, 25 2017 Dubai, UAE.

Recommended Global Neuroscience Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Renowned Speakers

Neuro Oncology 2017

Conference Highlights

To Collaborate Scientific Professionals around the World

Media Partners

Useful Links

Special Issues